Biotech & AI drug discoverySTAT — Biotech

STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved

German biotech Immatics is at a pivotal moment after a quarter century of work. The company is currently awaiting the Phase 3 results for its lead candidate drug targeting melanoma.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-21T08:30:00+00:00

Published here2026-10-21T10:05:58+00:00

Original source

STAT — Biotech

Media report · consult original reporting

Read the original ↗https://www.statnews.com/2026/10/21/immatics-cancer-cell-therapy-targets-prame-protein/

Original headline

STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.